{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:45:58Z","timestamp":1791776758082,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","award":["NXTGN-25-007"],"award-info":[{"award-number":["NXTGN-25-007"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA284133"],"award-info":[{"award-number":["R01CA284133"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajpath.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:32:42Z","timestamp":1785220362000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Microenvironmental Barriers to T-Cell Infiltration in Breast Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-9570","authenticated-orcid":false,"given":"Harold","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"DuCasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-9701","authenticated-orcid":false,"given":"Dennis","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2026.07.001_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cancers15010321","article-title":"Immunotherapy for triple-negative breast cancer: combination strategies to improve outcome","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2026.07.001_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","article-title":"Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors","volume":"8","author":"Abdou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","article-title":"Ductal carcinoma in situ of the breast: immune cell composition according to subtype","volume":"33","author":"Agahozo","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","article-title":"Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"International immuno-oncology biomarker working group: tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2026.07.001_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-025-00760-9","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment","volume":"11","author":"Taurelli","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2022.10.001","article-title":"Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis","volume":"66","author":"Li","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ajpath.2026.07.001_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-023-07242-1","article-title":"The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer","volume":"205","author":"\u00c7etin","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2026.07.001_bib11","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-020-01364-w","article-title":"Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up","volume":"22","author":"Lundgren","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130000","article-title":"Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients","volume":"4","author":"Egelston","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajpath.2026.07.001_bib14","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","article-title":"Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer","volume":"27","author":"Yam","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41523-025-00728-9","article-title":"Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Liang","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004647","article-title":"Prognostic significance of CD8+ T cell spatial biomarkers in ER+ and ER\u2212 breast cancer: a retrospective cohort study","volume":"22","author":"Walker","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib17","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1200\/JCO.2010.33.6446","article-title":"Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women","volume":"29","author":"Lee","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2026.07.001_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215381","article-title":"Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer","volume":"14","author":"Wen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2026.07.001_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.pas.0000213351.49767.0f","article-title":"BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays","volume":"31","author":"Bane","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","article-title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","volume":"31","author":"Barroso-Sousa","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-019-5402-1","article-title":"The neoepitope landscape of breast cancer: implications for immunotherapy","volume":"19","author":"Narang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140837","article-title":"MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation","volume":"131","author":"Fang","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2026.07.001_bib24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/PAS.0000000000001653","article-title":"MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1\/PD-L1 checkpoint inhibitors","volume":"45","author":"Dusenbery","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib25","first-page":"128","article-title":"Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis","volume":"4","author":"Garcia-Recio","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib26","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.07.001_bib27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10001","article-title":"Inhibition of LFA-1\/ICAM-1 and VLA-4\/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases","volume":"22","author":"Yusuf-Makagiansar","year":"2002","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ajpath.2026.07.001_bib28","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res"},{"issue":"191","key":"10.1016\/j.ajpath.2026.07.001_bib29","first-page":"2001","article-title":"High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin [beta]-producing dendritic cells in human breast cancer","volume":"2013","author":"Martinet","year":"1950","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib31","article-title":"Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2026.07.001_bib32","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.07.001_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","article-title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer","volume":"132","author":"Wang","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib34","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.4049\/jimmunol.1502376","article-title":"Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors","volume":"197","author":"Chheda","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1078-0432.CCR-11-3314","article-title":"Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry","volume":"19","author":"Mulligan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-023-02918-4","article-title":"NK cell-triggered CCL5\/IFN[gamma]-CXCL9\/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer","volume":"43","author":"Santana-Hern\u00e1ndez","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.clbc.2022.04.008","article-title":"Expression pattern and prognostic significance of chemokines in breast cancer: an integrated bioinformatics analysis","volume":"22","author":"Mehraj","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4270957","article-title":"Transcriptional expressions of CXCL9\/10\/12\/13 as prognosis factors in breast cancer","volume":"2020","author":"Li","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2026.07.001_bib40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.27767","article-title":"Distinct tumor protein p53 mutants in breast cancer subgroups","volume":"132","author":"Dumay","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib41","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/cam4.4652","article-title":"Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib42","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.breast.2013.07.005","article-title":"p53 in breast cancer subtypes and new insights into response to chemotherapy","volume":"22","author":"Bertheau","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ajpath.2026.07.001_bib43","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/s41416-022-01971-8","article-title":"Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246","volume":"127","author":"Zhou","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2026.07.001_bib45","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib46","article-title":"Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations","volume":"6","author":"Chen","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib47","first-page":"2005","article-title":"Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib48","article-title":"CD8+ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajpath.2026.07.001_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-017-0864-z","article-title":"Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes","volume":"19","author":"Prabhakaran","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib50","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2026.07.001_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4143\/crt.2016.215","article-title":"Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer","volume":"49","author":"Song","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2026.07.001_bib52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-22-2034","article-title":"Collagens in cancer: structural regulators and guardians of cancer progression","volume":"83","author":"De Martino","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2767-9764.CRC-25-0259","article-title":"Collagen-bearing exosomes from breast cancer-associated fibroblasts promote T-cell dysfunction","volume":"6","author":"Jana","year":"2026","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ajpath.2026.07.001_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","article-title":"Collagen density regulates the activity of tumor-infiltrating T cells","volume":"7","author":"Kuczek","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006720","article-title":"A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2026.07.001_bib57","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58688","article-title":"Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment","volume":"10","author":"Nicolas-Boluda","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.ajpath.2026.07.001_bib58","article-title":"Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade","volume":"6","author":"Khan","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib59","article-title":"Laminin [gamma]2-mediating T cell exclusion attenuates response to anti-PD-1 therapy","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajpath.2026.07.001_bib60","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/0008-5472.CAN-18-3060","article-title":"Remodeling the tumor microenvironment sensitizes breast tumors to anti-programmed death-ligand 1 immunotherapy","volume":"79","author":"Clift","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib61","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013270","article-title":"Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression","volume":"13","author":"Murdamoothoo","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib62","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1073\/pnas.1817652116","article-title":"Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.07.001_bib63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib64","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.07.001_bib65","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1073\/pnas.1819889116","article-title":"Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy","volume":"116","author":"Chauhan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.07.001_bib66","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41551-021-00766-1","article-title":"Solid stress impairs lymphocyte infiltration into lymph-node metastases","volume":"5","author":"Jones","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ajpath.2026.07.001_bib67","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.7150\/thno.36936","article-title":"TGF-[beta] inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity","volume":"10","author":"Panagi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ajpath.2026.07.001_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib69","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","article-title":"Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop","volume":"40","author":"Hua","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2026.07.001_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1172681","article-title":"Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy","volume":"14","author":"Das","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib71","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.devcel.2023.06.006","article-title":"LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer","volume":"58","author":"Anstee","year":"2023","journal-title":"Dev Cell"},{"key":"10.1016\/j.ajpath.2026.07.001_bib72","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2026.07.001_bib73","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4049\/jimmunol.0804253","article-title":"Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells","volume":"183","author":"Hanson","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib74","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1055-9965.EPI-18-0955","article-title":"Atypical chemokine receptor 1 (DARC\/ACKR1) in breast tumors is associated with survival, circulating chemokines, tumor-infiltrating immune cells, and African ancestry","volume":"28","author":"Jenkins","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajpath.2026.07.001_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207255","article-title":"MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors","volume":"13","author":"Juric","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2026.07.001_bib76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajpath.2026.07.001_bib77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2026.07.001_bib78","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2026.07.001_bib79","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.07.001_bib80","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1039\/c5ib00040h","article-title":"Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration","volume":"7","author":"Acerbi","year":"2015","journal-title":"Integr Bio (Camb)"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:12:09Z","timestamp":1791774729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944026002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":80,"alternative-id":["S0002944026002038"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.07.001","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Microenvironmental Barriers to T-Cell Infiltration in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}